contributor
- Calder, Christopher Sub-Investigator - 2006
A Phase II, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Finding Study to Evaluate the Efficacy and Safety of 20 mg, 40 mg and 80 mg of MCC-257 in Patients with Mild to Moderate Diabetic Polyneuropathy, Mitsubishi.
Grant
- Affiliation